Lupin's Goa facility may face regulatory action, says USFDA

The USFDA has stated that it may withhold approval of any pending
applications or supplements in which this facility is listed," it
added.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupins-goa-facility-may-face-regulatory-action-says-usfda/articleshow/69586425.cms

Comments

Popular posts from this blog

Lupin, Aurobindo units recall products in US market

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply

Data Analyst Jobs – Life Sciences Apply at Cognizant